Immix Biopharma, Inc. (NASDAQ:IMMX) Given Consensus Rating of “Moderate Buy” by Brokerages

Immix Biopharma, Inc. (NASDAQ:IMMX) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $20.7143.

IMMX has been the topic of several recent research reports. Bank of America started coverage on Immix Biopharma in a report on Thursday, June 18th. They issued a “buy” rating and a $27.00 price target on the stock. Lifesci Capital started coverage on Immix Biopharma in a report on Wednesday, June 17th. They set an “outperform” rating and a $19.00 price objective for the company. Needham & Company LLC began coverage on Immix Biopharma in a report on Wednesday, July 22nd. They issued a “buy” rating and a $21.00 target price on the stock. Citigroup started coverage on shares of Immix Biopharma in a research report on Thursday, June 18th. They issued a “buy” rating for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Friday, July 17th.

Immix Biopharma Price Performance

IMMX stock opened at $9.54 on Thursday. The company’s 50-day moving average is $9.34 and its 200-day moving average is $8.78. The stock has a market capitalization of $519.07 million, a PE ratio of -10.37 and a beta of 0.11. Immix Biopharma has a 1 year low of $1.94 and a 1 year high of $12.14.

Immix Biopharma (NASDAQ:IMMX) last issued its earnings results on Thursday, May 7th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. On average, analysts anticipate that Immix Biopharma will post -0.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Allworth Financial LP bought a new stake in shares of Immix Biopharma during the fourth quarter worth about $30,000. Mathes Company Inc. bought a new position in Immix Biopharma in the 4th quarter valued at about $56,000. Balyasny Asset Management L.P. bought a new position in Immix Biopharma in the 4th quarter valued at about $67,000. Kera Capital Partners Inc. acquired a new position in Immix Biopharma during the 4th quarter valued at about $68,000. Finally, Velan Capital Investment Management LP boosted its stake in Immix Biopharma by 40.0% during the 3rd quarter. Velan Capital Investment Management LP now owns 35,000 shares of the company’s stock valued at $73,000 after purchasing an additional 10,000 shares during the last quarter. 11.26% of the stock is currently owned by institutional investors and hedge funds.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.